ReproCELL
Beltsville, Maryland, United States · Founded 2003
About ReproCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.
Company Facts
- Founded: 2003
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Funding stage: IPO
- Last round: Grant (Oct 2025)
- Ticker: tyo:4978
- Website: reprocell.com
- Phone: +81 814 547-5388
Industries & Categories
Biotechnology, Health Care, Manufacturing, Test and Measurement
Social Profiles
Canonical: https://fsome.com/organization/reprocell-2545635 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.